ESO, CNIO and NRCO Conference on Familial Cancer 19/05/2016 – 20/05/2016, Madrid, Spain Chairs: R. Eeles, UK – W.D. Foulkes, CA – M. Robledo, ES – H. Vasen, NL The ESO, CNIO and NRCO Conference [more]
The impact chemotherapy can have on the ability to think clearly is well recognised. Less is known, however, about the cognitive effect of endocrine therapies, which in the adjuvant breast cancer setting are being prescribed [more]
Most people carrying harmful BRCA mutations only find out after they are diagnosed with cancer, and often not even then. Population screening is costly and the results can be hard to interpret. But should we [more]
The beta-carotene fiasco warned oncologists off suggesting supplements on the basis of observational studies. But with vitamin D now in the spotlight, how should doctors respond when their patients ask if it could help? A [more]
Screening breast cancer patients for lymphoedema makes it possible to identify problems early and take action to halt its progression. Oncologists have an important role to play, particularly given the rise in lymphoedema rates that [more]
The European Commission is developing a Europe-wide accreditation scheme for breast centres to push up standards of diagnosis and care. Here experts from both sides of the Atlantic take a look at existing schemes, the [more]
Will pathology services need a serious overhaul if they are to deliver the accuracy required for precision medicine? Two European initiatives are trying to build the case for change in this least visible of cancer [more]